Equities

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)8.60
  • Today's Change0.21 / 2.50%
  • Shares traded3.46m
  • 1 Year change-83.20%
  • Beta1.1482
Data delayed at least 15 minutes, as of Nov 14 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments9441,3161,550
Total Receivables, Net3284150
Total Inventory0.054.363.36
Prepaid expenses204519
Other current assets, total5.470.490.70
Total current assets1,0021,4501,723
Property, plant & equipment, net397716146
Goodwill, net496021
Intangibles, net8311122
Long term investments79114115
Note receivable - long term14--0
Other long term assets1.508944
Total assets1,6652,5392,071
LIABILITIES
Accounts payable9.32108.19
Accrued expenses11011593
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total444833
Total current liabilities164173135
Total long term debt0022
Total debt0022
Deferred income tax------
Minority interest0062
Other liabilities, total404630347
Total liabilities568803566
SHAREHOLDERS EQUITY
Common stock0.200.190.16
Additional paid-in capital6,3866,1363,805
Retained earnings (accumulated deficit)(5291)(4398)(2298)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total1.48(2.63)(1.72)
Total equity1,0971,7361,505
Total liabilities & shareholders' equity1,6652,5392,071
Total common shares outstanding514588369
Treasury shares - common primary issue2.872.771.30
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.